How do we approach acquired resistance to targeted therapies in lung cancer?

How do we approach acquired resistance to targeted therapies in lung cancer?

Da: GRACEcast
0 0 7 anni fa
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.

Seguici su Facebook